South Africa's Aspen unit to buy drug portfolio from GSK
JOHANNESBURG (Reuters) - Aspen Pharmacare (APNJ.J) said on Wednesday its subsidiary, Aspen Global, will pay 172 million pounds ($269.79 million) for GlaxoSmithKine Plc's (GSK.L) pharmaceutical products distributed in Australia.
Aspen said in a statement that the purchase price for the 25 pharmaceutical products was subject to a small reduction should the deal not be completed by October 31.
It said the deal will be funded from new offshore debt facilities and that Aspen Australia was expected to distribute the products.
The deal was subject to regulatory approvals from Australian authorities, the company said.
Aspen also announced in April that it would pay $263 million for GSK's international over-the-counter brands.
(Reporting by Olivia Kumwenda; Editing by David Cowell)
- Tweet this
- Share this
- Digg this
- Boxer Sarita Devi faces action after refusing medal at Asian Games
- Brookfield wins Revel Casino auction, but loser vows to fight
- CANADA STOCKS-TSX fall gets deeper as financial, energy shares drag
- UPDATE 2-EU-Russia gas duel deepens with Slovakia supply cut
- Billionaire Detroit business leader says "blight is like a cancer"